Prakash Varghese, MD
Psychiatry · East Chicago, INNPI 1356336192
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 614 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 614 payments — averaging $18.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Lundbeck LLC$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Vanda Pharmaceuticals Inc.$1K
- Johnson & Johnson$1K
- plus $4K from 18 others
What the payments were for
- Food & beverage$11,23999%
- Education$1201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 83 | $1,543 |
| Teva Pharmaceuticals USA, Inc. | 68 | $1,273 |
| Lundbeck LLC | 80 | $1,227 |
| Otsuka America Pharmaceutical, Inc. | 68 | $1,225 |
| Vanda Pharmaceuticals Inc. | 44 | $1,139 |
| Johnson & Johnson | 66 | $1,130 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 48 | $925 |
| Alkermes, Inc. | 46 | $754 |
| Neurocrine Biosciences, Inc. | 34 | $709 |
| E.r. Squibb & Sons, L.L.C. | 18 | $349 |
| Axsome Therapeutics, Inc. | 9 | $208 |
| Merck | 10 | $150 |
| Almatica Pharma LLC | 8 | $134 |
| Sunovion Pharmaceuticals Inc. | 8 | $131 |
| Indivior Inc. | 8 | $130 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $102 |
| Supernus Pharmaceuticals, Inc. | 1 | $50 |
| Luye Pharma (USA) Ltd. | 2 | $48 |
| Shire North American Group Inc | 2 | $32 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Tris Pharma Inc | 1 | $22 |
| Noven Therapeutics, LLC | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $14 |
How this compares
$11,359 in reported general payments places this provider in the 90th percentile of 514 psychiatry providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 109 | $376,336 |
| RexultiBrexpiprazole | 50 | $73,477 |
| Lurasidone Hcl | 155 | $61,599 |
| AustedoDeutetrabenazine | 17 | $58,649 |
| Risperdal ConstaRisperidone Microspheres | 22 | $27,955 |
| TrintellixVortioxetine Hydrobromide | 56 | $27,572 |
| VraylarCariprazine Hcl | 14 | $20,968 |
| Aripiprazole | 249 | $19,259 |
| LatudaLurasidone Hcl | 11 | $16,011 |
| Ziprasidone Hcl | 60 | $10,304 |
| Chlorpromazine Hcl | 27 | $9,282 |
| Olanzapine | 139 | $7,488 |
| Quetiapine Fumarate | 429 | $6,908 |
| Paliperidone ErPaliperidone | 22 | $6,257 |
| Fluvoxamine Maleate ErFluvoxamine Maleate | 14 | $5,886 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $1,130 | $404,292131 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,225 | $73,47750 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $1,273 | $58,64917 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $102 | $27,57256 claims |
| AbbVieVraylar | $1,543 | $20,96814 claims |
| Sunovion Pharmaceuticals Inc.Latuda | $131 | $16,01111 claims |
| MerckBelsomra | $150 | $5,09013 claims |
| Almatica Pharma LLCSertraline Hcl | $134 | $1,654255 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 514 psychiatry providers in Indiana.
Other psychiatry in East Chicago
- Joon LeeEast Chicago$11K
- Stephane DegraffEast Chicago$6K
- Steven PaulCarmel$2.9M
- Jay FawverAngola$1.4M
- Suhayl NasrMichigan City$739K
- Christopher BojrabCarmel$713K
- Joseph FanelliMunster$443K
- Eric JaggersJeffersonville$260K
- Larry LambertsonFort Wayne$208K
- Louis CadyNewburgh$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.